For migraine patients who'd run out of options: 60% felt much better

Some migraine patients try one preventive treatment after another with no relief. In Lundbeck's THRIVE trial, people with migraine who hadn't responded to a previous CGRP-targeting preventive were given eptinezumab — and at six months, 60% of those still in the trial said they felt 'much improved' or 'very much improved.' The trial was the first designed specifically for patients in this hard-to-treat position.